Accelerated Partial Breast Not Inferior to Whole-breast Irradiation Following Surgery

Share this content:
Accelerated partial breast irradiation was not inferior to adjuvant whole-breast irradiation.
Accelerated partial breast irradiation was not inferior to adjuvant whole-breast irradiation.

Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy in patients with early breast cancer was not inferior to adjuvant whole-breast irradiation, according to results of a phase 3 randomized non-inferiority trial reported in the Lancet.1

Investigators looked at 5-year local control, disease-free survival, and overall survival to compare APBI with whole-breast irradiation in patients with stage 0, 1, and 2a breast cancer who had undergone breast-conserving surgery.

Between April 20, 2004, and July 30, 2009, a total of 1,184 patients in seven European countries were randomly assigned to receive either APBI (n=633) or whole-breast irradiation (n=551).

A follow-up 5 years later showed that 9 patients treated with APBI and 5 patients treated with whole-breast irradiation had a local recurrence. The cumulative recurrence rate was 1.44% (95% CI, 0.51-2.38) with APBI and 0.92% with whole-breast irradiation (95% CI, 0.12-1.73).

RELATED: American Cancer Society Updates Breast Cancer Screening Guidelines

In regard to safety, no grade 4 late side effects were reported and grade 2-3 late side effects to the skin occurred in 3.2% of patients treated with APBI compared with 5.7% of patients treated with whole-breast irradiation (P=.08). Grade 2-3 subcutaneous tissue side effects were reported in 7.6% of patients in the APBI group vs 6.3% in the whole-breast irradiation group (P=.46).

Reference

  1. Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial [published online ahead of print October 19, 2015]. Lancet. doi: 10.1016/S0140-6736(15)00471-7.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs